Oxybutynin chloride: alterations in drug delivery and improved therapeutic index

REFERENCES

• MCGROTHER C, RESNICK M, YALLA SV et al.: Epidemiology and etiology of urinary incontinence in the elderly. World J. Urel (1998) 16:3–9.
   Google Scholar
• KACHUR JF, PETERSON JS, CARTER JP, RZESZOTARSKI WJ, HANSON RC, NORONHA-BLOB L: Rand S enantiomers of oxybutynin: pharmacological effects in guinea-pig bladder and intestine. I Pharmacy]. Exp. Ther. (1988) 3:867–872.
   Google Scholar
• NORONHA-BLOB L, KACHUR JF: Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2, and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis, and salivary secretion in guinea-pigs. J. Pharmacy]. Exp. Ther. (1991) 256:562–567.
   PubMed Web of Science ®Google Scholar
• MALKOWICZ SB, WEIN AJ, RUGGIERI MR, LEVIN RM: Comparison of calcium antagonist properties of antispasmodic agents. J. Urel (1987) 138(3):667–670.
   Google Scholar
• TONINI M, RIZZI CA, PERUCCA E et al.: Depressant action of oxybutynin on the contractility of intestinal and urinary tract smooth muscle. I Pharmacy]. (1987) 39(2):103–107.
   Google Scholar
• YARKER YE, GOA KL, FITTON A: Oxybutynin. A review of its pharmacodynamic and pharmacolkinetic properties, and its therapeutic use in detrusor instability. Drugs Aging (1995) 6(3):243–262.
   Google Scholar
• PARK J, BAUER S, FREEMAN M, PETERS C: Oxybutynin chloride inhibits proliferation and suppresses gene expression in bladder smooth muscle cells. Urel (1999) 162:1110–1114.
   Google Scholar
• DOUCHAMPS J, DERENA F, STOCKIS A, GANGJI D, JUVENT M, HERCHUELZ A: The pharmacolkinetics of oxybutynin in man. Eur. Clin. Pharmacy]. (1988) 35(5):515–520.
   Google Scholar
• ••The most authoritative study of basic andclinical science data available on the compound Oxy.
   Google Scholar
• LINDEKE B, HALLSTROM G, JOHANSSON C, ERICSSON 0, OLSSON LI, STROMBERG S: Metabolism of oxybutynin: establishment of desethyloxybutynin and oxybutynin N-oxide formation in rat liver preparation using deuterium substitution and gas chromatographic mass spectrometric analysis. Biemed. Mass Spectrem. (1981) 8(10):506–513. 452 Expert Op/n. Pharmacother. (2002) 3(4)
   Google Scholar
• GILLBERG P, STEFFAN S: Pharmacological profile of DD 01 and desethyloxybutynin (DEOB) - the major metabolite of tolterodine and oxybutynin (OB) respectively.' Ural. (1997) 157:81–84.
   Google Scholar
• HUGHES KM, LANG JC, LAZARE R et al.: Measurement of oxybutynin and its N-desethyl metabolite in plasma and its application in pharmacokinetic studies in young, elderly, and frail elderly volunteers. Xenebietica (1992) 22(7):859–869.
   PubMed Web of Science ®Google Scholar
• WALDECK K, LARRSON B, ANDERSSON K-E: Comparison of oxybutynin and its active metabolite, N-desethyloxybutynin, in the human detrusor and parotid gland. I Ural. (1997) 157:1093–1097.
   Google Scholar
• •Superb description of differential activity and binding of parent and metabolite on the basis of target specificity.
   Google Scholar
• ILLETT KF, TEE LBG, REEVES PT, MINCHIN RF: Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacy]. Ther: (1990) 46:67–93.
   Google Scholar
• PAINE ME KHAIGHI M, FISHER JM et al.: Characterization of interintestinal variations in human CYP3A dependent metabolism. J. Pharmacy]. Exp. Ther. (1997) 283:1552–1562.
   Google Scholar
• APPELL RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology (1997) 50:91–96.
   Google Scholar
• •Summary of all data to that date on the tolterodine compound in clinical trials.
   Google Scholar
• HARVEY M-A, BAKER K, WELLS G: Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta analysis. Am. Obstet. Cynecel (2001) 185:56–61.
   Google Scholar
• NILVEBRANT L, ANDERSSON KE, GILLBERG PG, STAHL M, SPARF B: Tolterodine - a new bladder selective muscarinic agent. Eur. J. Pharmacy]. (1997) 327:195–207.
   PubMed Web of Science ®Google Scholar
• ADUBOFOUR K, KAJIWARA G, GOLDBERG C, KING-ANGELL J: Oxybutynin-induced heat stroke in an elderly patient. Ann. Pharmacether: (1996) 30:144–147.
   Google Scholar
• PIETZKO A, DIMPFEL W, SCHWANTES U, TOPFMEIER P: Influences of tropsium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur: Clin. Pharmacy]. (1994) 47:337–343.
   PubMed Web of Science ®Google Scholar
• DIMPFEL W, TODOROVA A, VONDERHEID-GUTH B: Electrophysiological evaluation of potential adverse drug effects of tolterodine, oxybutynin and trospium chloride on the central nervous system. J. Ural. (2000) 164:1005. Abstract.
   Google Scholar
• KATZ I, SANDS L, BILKER W, DIFILIPPO S, BOYCE A, D'ANGELO K: Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. JAGS (1998) 46:8–13.
   PubMed Web of Science ®Google Scholar
• DONELLAN CA, FOOK L, MCDONALD P, PLAYER JR: Oxybutynin and cognitive dysfunction. Br. Med. (1997) 315:1363–1364.
   Google Scholar
• STASKIN DR, APPELL RA, DMOCHOWSKI R, ALBRECHT D: Central nervous system adverse events with anticholinergic medication for overactive bladder. 2nd International Consultation on Incontinence. Paris, France (1–3 July 2001).
   Google Scholar
• KELLEHER CJ, CARD OZO LD, KHULLAR V, SALVATORE S: A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. °Enter Cyneel (1997) 104:988–993.
   Google Scholar
• MADERSBACHER H, KNOLL M: Intravesical application of oxybutynin: mode of action in controlling detrusor hyperreflexia. Preliminary results. Eur. Ural. (1995) 28(4):340–344.
   Google Scholar
• MASSAD CA, KOGAN BA, TRIGO-ROCHA FE: The pharmacokinetics of intravesical and oral oxybutynin chloride. J. Urel. (1992) 148:595–597.
   PubMedGoogle Scholar
• •Delineation of different types of pharmacological delivery and effects on serum concentrations.
   Google Scholar
• KATO K, KITADA S, CHUN A, WEIN AJ, LEVIN RIVI: In vitro intravesical installation of anitcholinergic, antispasmodic and calcium channel blocking agents (rabbit whole bladder model). Urology(1989) 141:1471–1474.
   Google Scholar
• BUYSE G, WALDECK K, VERPOORTEN C, BJORK H, CASAER P, ANDERSON KE: Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. " Urel. (1998) 160:892–896.
   PubMed Web of Science ®Google Scholar
• SATHYAN G, HU W, GUPTA SK: Lack of effect of food on the pharmacokinetics of an extended release oxybutynin formulation. J. Clin. Pharmacy]. (2001) 41:187–192.
   PubMedGoogle Scholar
• DMOCHOWSKI R, SATHYAN G, YE C, GUPTA SK: The effect of pH on drug release from extended release formulations of oxybutynin and tolterodine. 2' International Consultation on Incontinence. Paris, France (1–3 July 2001).
   Google Scholar
• SATHYAN G, HWANG S, GUPTA SK: Effect of doing time on the total intestinal transit time of non-disintegrating systems. Int. J. Pharmacel (2000) 204:47–51.
   PubMed Web of Science ®Google Scholar
• GUPTA SK, SATHYAN G: Pharmacokinetics of an oral once a day controlled release oxybutynin formulation compared with immediate release oxybutynin. Clin. Pharmacy]. (1999) 39:289–296.
   Google Scholar
• CHANCELLOR MB, APPELL RA, SATHYAN G, GUPTA S: A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate. Clin. Titer: (2001) 23(5):753–760.
   Google Scholar
• SATHYAN G, CHANCELLOR MB, GUPTA SK: Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br: J. Clin. Pharmacy]. (2001) 52:409–417.
   PubMed Web of Science ®Google Scholar
• ••The most comprehensive review ofpharmacodynarnics of OROS delivery and the effects on Oxy metabolism.
   Google Scholar
• SATHYAN G, HU W, CHANCELLOR MB, GUPTA SK: Comparison of CYP3A4 inhibitor effects on the stereoselective pharmacokinetics of extended release oxybutynin and conventional oxybutynin. Pharm. Sci. (1999) 1:2056–2059.
   Google Scholar
• ANDERSON RU, MOBLEY D, BLANK B, SALTZSTEIN D, SUSSET J, BROWN J: Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J. Ural. (1999) 161:1809–1812.
   PubMed Web of Science ®Google Scholar
• VERSI E, APPELL R, MOBLEY D, PATTON W, SALTZSTEIN D: Dry mouth with conventional and controlled release oxybutynin in urinary incontinence. Obstet. Cynecel (2000) 95(5):718–721.
   Google Scholar
• GLEASON DM, SUSSET J, WHITE C, MUNOZ DR, SAND PK: Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology (1999) 54:420–423.
   PubMed Web of Science ®Google Scholar
• GUPTA SK, SATHYAN G, LINDEMULDER EA, HO PL, SHEINER LB, AARONS 1: Quantitative characterization of therapeutic index: application of mixed effects modeling to evaluate oxybutynin dose efficacy and dose 453 Expert Op/n. Pharmacother. (2002) 3(4) side effect relationships. Clin. Pharmacol. Ther. (1999) 65(6):672–684.
   Google Scholar
• APPELL RA, SAND P, DMOCHOWSKI R et al.: Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT trial. Mayo Clin. Proc. (2001) 76:358–363.
   PubMed Web of Science ®Google Scholar
• •Comparator study providing direct head-to-head evaluation of most commonly prescribed agents for overactive bladder in the agent.
   Google Scholar
• SAND PK, APPELL RA, MIKLOS JR, DMOCHOWSKI RR, ALBRECHT D: Randomized double blind study to compare extended release oxybutynin and tolterodine for overactive bladder. Obstet. Cynecol. (2001) 97(4):49.
   Google Scholar
• BIRNS J, LUKKARI E, MALONE-LEE JG: A randomized controlled trial comparing the efficacy of controlled release oxybutynin tablets (10 gm once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. Br: J. Urol. (2000) 85:793–798.
   Google Scholar
• LUKKARI E, ARANKO K, JUHAKOSKI A, HAKONEN T, NEUVONEN P: Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled release tablet. Pharmacol. Toxicol (1997) 81:31–34.
   Google Scholar
• APPELL R, DIOKNO A, ANTOCI J, LABASKY R: One year, prospective, open label trial of controlled release oxybutynin for overactive bladder in a community based population. American Geriatric Society (2000). Poster.
   Google Scholar
• TUTTLE J, ANTOCI J: Controlled release oxybutynin for overactive bladder in an elderly population. American Geriatric Society (2000). Poster.
   Google Scholar
• ARIKIAN S, CASCIANO J, DOYLE J, TARRIDE J-E, CASCIANO R: A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Managed Care Interface (2000)88–94.
   Google Scholar